Flores-Calderón J, Gómez-Díaz RA, Rodríguez-Gómez G, Morán-Villota S

Language: English
References: 35
Page: 279-283
PDF size: 56.22 Kb.

Text Extraction

Background: Elevated ALT is an indirect marker of NAFLD in patients with non-alcohol abuse and without other known causes of chronic hepatitis. Obesity, type 2 diabetes and some dyslipidemias are associated to this condition. The purpose of this study was to determine the frequency of increased aminotransferases and associated metabolic anomalies among overweight and obese children. Methods: Children from an elementary school with obesity or overweight were included. Medical history and anthropometrics measurements were recorded and serum liver function tests, lipid profile, glucose and insulin levels, and HOMA index were determined. NAFLD diagnosis was considered in those children with ALT › 40 U/L and AST/ALT ratio ‹ 1 after exclusion of other causes of chronic hepatitis. Results: Increase ALT levels (› 40 U/L) were found in 34/ 80 (42%) obese and overweight children; mean age was 9.5 ± 1.1 years and mean BMI of 25.8 ± 3. The metabolic abnormalities in the study group were similar, there were no differences in insulin concentration, insulin resistance determined by HOMA-IR Index, serum lipid profile and serum glucose between children with or without increased ALT. Conclusions: The frequency (42%) of elevated ALT levels in children with excess body weight in this study was greater to those reported in other pediatric populations. There were no differences among the metabolic alterations with or without increased ALT; these findings support that the principal pathogenic factor involved in the development of the hepatic injury may be located in the liver.

REFERENCES

1. Falck-Yttery, Mc Cullough AJ, Younossi M, Marchesini G. Clinical features and natural history of non-alcoholic steatosis syndromes. Sem Liver Disease 2001; 21: 17-26.

2. Manton ND, Lipsett J, Moore DJ, Davidson GP, Bourne AJ, Couper RTL. Nonalcoholic steatohepatitis in children and adolescents. Med J Aust 2000; 173: 476-79.

3. Baldridge AD, Perez-Atayde AR, Graeme-Cook F, Higgins L, Lavine JE: Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr 1995; 127: 700-4.

4. Kinugasha A, Tsunamoto K, Furukawa T, Sawada T, Kusonoki T, Shimada N. Fatty liver and its fibrous changes found in simple obesity of children. J Pediatr Gastroenterol Nutr 1984; 3: 408-14.

5. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000; 30: 48-53.

6. Strauss R, Barlow S, Dietz W. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr 2000; 136: 727-33.

7. Franzese A, Vajro P, Argenziano A, Puzziello A, Iannucci MP, Saviano MC, Brunetti F, et al. Liver involvement in obese children: ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997; 42: 1428-32.

8. Tominaga K, Kurata JH, Chen YK, Fujumoto E, Miyagawa S, Ichiro A, Kusano Y. Prevalence of fatty liver in Japanese children and relationship to obesity: an epidemiological ultrasonographic survey. Dig Dis Sci 1995; 40: 2002-9.

9. Tazawa Noguchi H, Nishinomiya F, Takada G. Serum alanine aminotransferase activity in obese children. Acta Pediatr 1997; 86: 238-41.

10. Ballentani S. Prevalence and risk factors for Hepatic Steatosis in North Italy. Ann Intern Med 2000; 132: 112-17.

11. Rivera DJ, Shamah LT, Villalpando HS, González CT, Hernández PB, Sepúlveda J. Encuesta Nacional de Nutrición 1999. Estado de Nutrición de niños y mujeres en México. Cuernavaca, Morelos, México. Instituto Nacional de Salud Pública, 2001.

12. Maynard LM, Wisemandle W, Roche AF, Cameron W, Guo Sh, Siervogel RM. Childhood Body Composition in relation to Body Mass Index. Pediatrics 2001; 107: 344-50.

13. National Center for Health Statistics National Health and Nutrition examination survey. CDC Growth Charts: Body Mass index for Age. United States 2000.

14. Expert Panel on Blood Cholesterol levels in children and adolescents. National Cholesterol Education Program report. Pediatrics 1992; 89 (suppl): 525-84.

15. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003; 26: 3320-25.

16. Huang TT, Johnson MS, Goran MI. Development of a Prediction Equation for Insulin sensitivity from anthropometry and fasting insulin in prepubertal and early pubertal children. Diabetes Care 2002; 25: 1203-10.

17. Fishbein MH, Miner M, Mogren Ch, Chaleckson J. The spectrum of fatty liver in obese children and the relationship of serum aminotransferases to severity of steatosis. J Pediatr Gastroenterol Nutr 2003; 36: 54-61.

18. Bergomi A, Lughetti L, Corciulo N. Italian multicenter study on liver damage in pediatric obesity (abstract). Int J Obes Relat Metabol Disord 1998; 22 (suppl 4): S22.

19. Powell EE, Cooksley WGE, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis. A follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.

20. Kaplan MM. Alanine Aminotransferase levels: What’s normal? Ann Inter Med 2002; 137: 49-51.

21. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.

22. Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 2003; 143: 500-5.

23. Vajro P, Fontanella A, Perna C, Orso G, Tedesco M, DeVicenzo A. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994; 125: 239-41.

24. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut 2002; 50: 585-88.

25. Vajro P, Franzese A, Valerio G, Iannucci MP, Aragione N. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr 2000; 136: 739-43.

26. Srinivasan SR, Fronton MG, Berenson GS. Longitudinal changes in risk variables of insulin resistance syndrome from childhood to young adulthood in offspring of parents with type 2 diabetes: The Begolusa Heart Study. Metabolism 2003; 52: 443-50.

27. Weiss R, Dziura J, Burgert T, Tamborlane WV, Taksali SE, Yeckel C, Allen K, Lopes M, et al. Obesity and the Metabolic Syndrome in Children and Adolescents. N Engl J Med 2004; 350: 2362-74.

28. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough A, et al. Nonalcoholic fatty liver Disease. A feature of the Metabolic Syndrome. Diabetes 2001; 50: 1844-50.

29. Evans HM, Baumann U, McLiernan PJ, Kirk JMW, Shaikh G, Kelly DA. Fatty liver disease in children in the West Midlands, United Kingdom. J Pediatr Gastroenterol Nutr 2004; 39 (suppl 1): S52.

30. Neuschwander-Tetri, Caldwell SH. Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference. Hepatology 2003; 37: 1202-09.

31. Maffeis C, Moghetti P, Grezzani A, Clementi M, Gaudino R, Tato L. Insulin resistance and the persistence of obesity from childhood into adulthood. J Clin Endocrinol Metab 2002; 87: 71-76.

32. Bellizzi M, Dietz W. Workshop on childhood obesity: Summary of the discussion. Am J Clin Nutr 1999; 70: 173S-5S.

33. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136: 734-38.

34. Angulo P, Lindor KD. Treatment of Nonalcoholic fatty liver. Present and emerging therapies. Sem Liver Diseases 200; 21: 81-88.

35. Lok AS, McMahon BJ. Chronic hepatitis B: Update of recommendations. Hepatology 2004; 39: 857-61.